Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotie to take over Newron for EUR45m
Following the acquisition, Newron will merge into Biotie and all of its assets, rights, debts and other liabilities will transfer to Biotie. The new biopharmaceutical company which will
Following the acquisition, Newron will merge into Biotie and all of its assets, rights, debts and other liabilities will transfer to Biotie. The new biopharmaceutical company which will
As per the deal, Lonza will supply Mesoblast’s clinical and long-term commercial MPC product needs globally. Mesoblast can trigger a process requiring Lonza to construct a purpose-built manufacturing
As per the terms of the deal, CDRD Ventures will drive the development of projects together with Roche. The agreement allows CVI to support Canadian health researchers for
Watson’s Norethindrone and Ethinyl Estradiol Tablets (Chewable), 0.4mg/0.035mg and Ferrous Fumarate Tablets (Chewable), 75mg is the generic of Ireland-based Warner Chilcott’s Femcon Fe. Ethinyl estradiol and norethindrone are
PrognoCIS enables physicians to qualify for federal funding to assist with EMR costs. PrognoCIS EMR system features system-level and encounter-level dashboards and helps track and monitor the customer’s
With this application, the doctors can view critical laboratory, pathology and radiology results, demographics, notes, patient lists and trending data from multiple sources and render informed decisions via
Under the agreement, TS Pharma will commercialize the product in Antigua, Aruba, Bahamas, Barbados, Belize, Bermuda, Cayman Islands, Costa Rica, Curacao, , Dominican Republic, Guatemala, Haiti, Honduras, Jamaica,
The 24-week randomized placebo-controlled, double-blind, multi-center Impres trial involving 202 patients is intended to evaluate the efficacy and safety of oral QTI571 as an add-on therapy in the
The Belief registration trial is a multicenter, open-label, single arm efficacy and safety study in patients with relapsed or refractory PTCL, who have failed at least one prior
Under the contract, the companies will work on drug metabolism and pharmacokinetics studies, including CYP inhibition, metabolic identification and stability. It will also include metabolic identification and stability,